A comparison of a new multinomial stopping rule with stopping rules of Fleming and Gehan in single arm phase II cancer clinical trials

BMC Medical Research Methodology

Volumn 11, Issue , 2011, Pages

  Goffin, John R ^a   Pond, Greg R ^b   Tu, Dongsheng ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; BIOASSAY; COMPARATIVE STUDY; HUMAN; METHODOLOGY; NEOPLASM; PHASE 2 CLINICAL TRIAL (TOPIC); SAMPLE SIZE; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE II AS TOPIC; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 79959252371     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-11-95     Document Type: Article

References (20)

1. The price of innovation: new estimates of drug development costs. JA DiMasi RW Hansen HG Grabowski, J Health Econ 2003 22 151 185 10.1016/S0167-6296(02)00126-1 12606142 (Pubitemid 36279392)
2. Oncology's trials. B Booth R Glassman P Ma, Nat Rev Drug Discov 2003 2 609 610 10.1038/nrd1158 12908467
3. Economics of new oncology drug development. JA DiMasi HG Grabowski, J Clin Oncol 2007 25 209 216 10.1200/JCO.2006.09.0803 17210942 (Pubitemid 350003036)
4. Alternate endpoints for screening phase II studies. N Dhani D Tu DJ Sargent L Seymour MJ Moore, Clin Cancer Res 2009 15 1873 1882 10.1158/1078-0432.CCR-08-2034 19276273
5. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. EA Gehan, J Chronic Dis 1961 13 346 353 10.1016/0021-9681(61)90060-1 13704181
6. One-sample multiple testing procedure for phase II clinical trials. TR Fleming, Biometrics 1982 38 143 151 10.2307/2530297 7082756
7. Optimal two-stage designs for phase II clinical trials. R Simon, Control Clin Trials 1989 10 1 10 10.1016/0197-2456(89)90015-9 2702835 (Pubitemid 19099520)
8. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. RH El-Maraghi EA Eisenhauer, J Clin Oncol 2008 26 1346 1354 10.1200/JCO.2007.13.5913 18285606
9. Five-year change in statistical designs of phase II trials published in leading cancer journals. S Thezenas J Duffour S Culine A Kramar, Eur J Cancer 2004 40 1244 1249 10.1016/j.ejca.2004.01.008 15110889 (Pubitemid 38526344)
10. Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. A Cesano SR Lane R Poulin G Ross SZ Fields, Int J Oncol 1999 15 1233 1238 10568833
11. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - report of a Canadian multicenter randomized trial. E Rapp JL Pater A Willan Y Cormier N Murray WK Evans DI Hodson DA Clark R Feld AM Arnold,, et al. J Clin Oncol 1988 6 633 641 2833577
12. Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer. I Sekine T Tamura H Kunitoh K Kubota T Shinkai Y Kamiya N Saijo, Ann Oncol 1999 10 731 733 10.1023/A:1008303921033 10442198 (Pubitemid 29342381)
13. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. PN Lara Jr MW Redman K Kelly MJ Edelman SK Williamson JJ Crowley DR Gandara, J Clin Oncol 2008 26 463 467 10.1200/JCO.2007.13.0344 18202421 (Pubitemid 351171700)
14. Multinomial phase II cancer trials incorporating response and early progression. B Zee D Melnychuk J Dancey E Eisenhauer, J Biopharm Stat 1999 9 351 363 10.1081/BIP-100101181 10379698 (Pubitemid 29262953)
15. Multinomial phase II trial designs. B Freidlin J Dancey EL Korn B Zee E Eisenhauer, J Clin Oncol 2002 20 599 11786592
16. Phase II stopping rules that employ response rates and early progression. JR Goffin D Tu, J Clin Oncol 2008 26 3715 3720 10.1200/JCO.2007.14.1044 18669457
17. Application of a new multinomial phase II stopping rule using response and early progression. S Dent B Zee J Dancey A Hanauske J Wanders E Eisenhauer, J Clin Oncol 2001 19 785 791 11157032 (Pubitemid 32119094)
18. Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer. DJ Gallagher MI Milowsky SR Gerst N Ishill J Riches A Regazzi MG Boyle A Trout AM Flaherty DF Bajorin, Journal of Clinical Oncology 2010 28 1373 1379 10.1200/JCO.2009.25.3922 20142593
19. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. JH Schiller T Larson SH Ou S Limentani A Sandler E Vokes S Kim K Liau P Bycott AJ Olszanski,, et al. J Clin Oncol 2009 27 3836 3841 10.1200/JCO.2008.20.8355 19597027
20. An optimal two-stage phase II design utilizing complete and partial response information separately. KS Panageas A Smith M Gonen PB Chapman, Control Clin Trials 2002 23 367 379 10.1016/S0197-2456(02)00217-9 12161080 (Pubitemid 34874889)